Picture Berlin Partner Special Topic Well-trained Professionals 650x100px

Organisation › Details

US Patent and Trademark Office (USPTO)

https://www.uspto.gov

	Start	1998-05-27 existent
	Group	United States (govt)
	Industry	IP services

	City	n. a.
		Address record changed: 2020-12-02

Basic data	Employees	n. a.


		Record changed: 2023-11-10

Picture EBD Group Biotech Showcase 2024 San Francisco 650x200px

More documents for United States (govt)

[1] Valneva S.E.. (11/10/23). "Press Release: Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, Ixchiq". Saint Herblain....
[2] Immunic, Inc.. (11/2/23). "Press Release: Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts". New York, NY....
[3] Santhera Pharmaceuticals Holding AG. (10/27/23). "Press Release: Santhera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy [Ad hoc announcement pursuant to Art. 53 LR]". Pratteln....
[4] MetrioPharm AG. (10/25/23). "Press Release: MetrioPharm Receives Rare Pediatric Disease Designation (RPDD) for MP1032 from the U.S. FDA". Zurich....
[5] Immatics N.V.. (10/24/23). "Press Release: Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy". Houston, TX & Tübingen....
[6] Agomab Therapeutics N.V.. (10/5/23). "Press Release: Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn’s Disease and Starts STENOVA Phase 2a Clinical Trial". Ghent....
[7] 4SC AG. (9/27/23). "Press Release: 4SC Receives Orphan Drug Designation (ODD) for Resminostat (Kinselby) in CTCL from the US FDA". Planegg-Martinsried....
[8] Valneva S.E.. (9/25/23). "Press Release: Valneva Announces New Ixiaro Supply Contract with the U.S. Government Worth a Minimum of $32 Million". Saint Herblain....
[9] BioProtect Ltd.. (8/28/23). "Press Release: BioProtect Receives FDA’s Clearance for Its Biodegradable Balloon for Rectal Protection during Prostate Cancer Radiation Therapy". Tzur Yigal....
[10] ADC Therapeutics S.A.. (7/20/23). "Press Release: ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of Zynlonta (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients". Lausanne....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]